Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix combination therapy randomized withdrawal study in women with heavy menstrual bleeding associated with uterine fibroids
2018-001368-43Phase 3Completed
- Sponsor
- Myovant Sciences
- Start
- Nov 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fibromyoma (LM) and hypermenorrhea comparing Relugolix + estradiol + norethindrone acetate with Placebo (2 arms). Primary endpoint: Maintenance of menstrual blood loss <80 mL at Week 76. Started Nov 2018; status: completed.
02
Drugs
tissue-plasminogen activatorestradiolnorethisterone acetate
03
Conditions
Fibromyoma (LM)hypermenorrhea
Beyond the preview
Go deeper on 2018-001368-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001368-43.